The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis

被引:8
|
作者
Lama, Niki [1 ]
Briasoulis, Alexandros [2 ]
Karavasilis, Efstratios [1 ]
Stamatelopoulos, Kimon [2 ]
Chasouraki, Angeliki [2 ]
Alexopoulou, Efthymia [1 ]
Spiliopoulos, Stavros [1 ]
Theodorakakou, Foteini [2 ]
Dimopoulos, Meletios Athanasios [2 ]
Kastritis, Efstathios [2 ]
Kelekis, Nikolaos L. [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Res Unit Radiol & Med Imaging, Dept Radiol 2, Med Sch,Fac Med, Papadiamantopoulou 19, Athens 11528, Greece
[2] Natl Kapodistrian Univ Athens, Fac Med, Med Sch, Dept Clin Therapeut, Vasilissis Sofias 80, Athens 11528, Greece
关键词
Amyloidosis; CMR; Spleen involvement; INTERSTITIAL VOLUME;
D O I
10.1186/s13244-022-01194-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives Cardiac magnetic resonance (CMR) imaging is a key test in the diagnosis of cardiac amyloidosis (CA). Extracardiac involvement is common in light chain (AL) amyloidosis and MRI findings may assist in its diagnosis. We sought to investigate the utility of splenic CMR parameters for the diagnosis of CA. Methods Thirty-four patients with AL amyloidosis and 32 patients with severe left ventricular hypertrophy in the setting of aortic stenosis (LVH-AS) who completed 3T cardiac MRI at the time of their diagnosis of AL or LVH-AS were assessed with T1, T2 (modified Look-Locker inversion recovery), extracellular volume (ECV) mapping, and late gadolinium enhancement (LGE) imaging of the heart and spleen. Results Age, left ventricular mass index, wall thickness, ejection fraction, and splenic dimensions did not differ significantly between groups. All AL patients had cardiac involvement. T1 and T2 spleen mapping did not differ significantly between groups but AL patients had higher median ECV in the spleen than in LVH-AS (AL 46.9%, LVH-AS: 31%, p < 0.001), and significantly lower short tau inversion recovery ratio (AL: 1.7, LVH-AS: 2.7, p < 0.001) both with very good diagnostic performance to diagnose AL. We identified 16 AL patients with spleen involvement and 16 without. Spleen ECV and "normalized" spleen ratio, defined as the ratio of spleen LGE to muscle values exhibited strong correlation and had excellent diagnostic performance to discriminate those with spleen involvement. Conclusion Our findings show that spleen CMR parameters can identify spleen involvement in AL patients and differentiate them from those without AL amyloidosis.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Light-chain cardiac amyloidosis: A multimodality approach
    Erick Alexanderson-Rosas
    Mara Escudero-Salamanca
    Jesus A. Garcia-Diaz
    Ricardo Alvarez-Santana
    Roberto Cano-Zarate
    Julio Mamani-Tito
    Isabel Carvajal-Juarez
    Nilda Espinola-Zavaleta
    Journal of Nuclear Cardiology, 2020, 27 : 2432 - 2435
  • [32] The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis
    Nasr, Samih H.
    Said, Samar M.
    Valeri, Anthony M.
    Sethi, Sanjeev
    Fidler, Mary E.
    Cornell, Lynn D.
    Gertz, Morie A.
    Dispenzieri, Angela
    Buadi, Francis K.
    Vrana, Julie A.
    Theis, Jason D.
    Dogan, Ahmet
    Leung, Nelson
    KIDNEY INTERNATIONAL, 2013, 83 (03) : 463 - 470
  • [33] Light-chain (AL) amyloidosis: Diagnosis and treatment
    Sanchorawala, Vaishali
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06): : 1331 - 1341
  • [34] Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy
    Muchtar, Eli
    Buadi, Francis K.
    Dispenzieri, Angela
    Gertz, Morie A.
    ACTA HAEMATOLOGICA, 2016, 135 (03) : 172 - 190
  • [35] Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Dispenzieri, Angela
    Dingli, David
    Kumar, Shaji K.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    Hayman, Suzanne
    Buadi, Frances
    Zeldenrust, Stephen
    Leung, Nelson
    Detweiler-Short, Kristen
    Lust, John A.
    Russell, Stephen J.
    Kyle, Robert A.
    Gertz, Morie A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) : 757 - 759
  • [36] Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment
    Caccialanza, Riccardo
    Palladini, Giovanni
    Klersy, Catherine
    Cereda, Emanuele
    Bonardi, Chiara
    Cameletti, Barbara
    Quarleri, Lara
    Montagna, Elisabetta
    Foli, Andrea
    Milani, Paolo
    Lavatelli, Francesca
    Marena, Carlo
    Merlini, Giampaolo
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2014, 38 (07) : 891 - 894
  • [37] Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study
    Fontana, Marianna
    Banypersad, Sanjay M.
    Treibel, Thomas A.
    Abdel-Gadir, Amna
    Maestrini, Viviana
    Lane, Thirusha
    Gilbertson, Janet A.
    Hutt, David F.
    Lachmann, Helen J.
    Whelan, Carol J.
    Wechalekar, Ashutosh D.
    Herrey, Anna S.
    Gillmore, Julian D.
    Hawkins, Philip N.
    Moon, James C.
    RADIOLOGY, 2015, 277 (02) : 388 - 397
  • [38] UTILITY OF SUBCUTANEOUS FAT ASPIRATION FOR THE DIAGNOSIS OF SYSTEMIC AMYLOIDOSIS (IMMUNOGLOBULIN LIGHT CHAIN)
    GERTZ, MA
    LI, CY
    SHIRAHAMA, T
    KYLE, RA
    ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (04) : 929 - 933
  • [39] Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
    Kastritis, E.
    Palladini, G.
    Minnema, M. C.
    Wechalekar, A. D.
    Jaccard, A.
    Lee, H. C.
    Sanchorawala, V
    Gibbs, S.
    Mollee, P.
    Venner, C. P.
    Lu, J.
    Schonland, S.
    Gatt, M. E.
    Suzuki, K.
    Kim, K.
    Cibeira, M. T.
    Beksac, M.
    Libby, E.
    Valent, J.
    Hungria, V
    Wong, S. W.
    Rosenzweig, M.
    Bumma, N.
    Huart, A.
    Dimopoulos, M. A.
    Bhutani, D.
    Waxman, A. J.
    Goodman, S. A.
    Zonder, J. A.
    Lam, S.
    Song, K.
    Hansen, T.
    Manier, S.
    Roeloffzen, W.
    Jamroziak, K.
    Kwok, F.
    Shimazaki, C.
    Kim, J-S
    Crusoe, E.
    Ahmadi, T.
    Tran, N. P.
    Qin, X.
    Vasey, S. Y.
    Tromp, B.
    Schecter, J. M.
    Weiss, B. M.
    Zhuang, S. H.
    Vermeulen, J.
    Merlini, G.
    Comenzo, R. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01): : 46 - 58
  • [40] An evaluation of current treatment options for immunoglobulin light-chain amyloidosis
    Sachchithanantham, Sajitha
    Wechalekar, Ashutosh D.
    Hawkins, Philip N.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (03): : 229 - 244